Literature DB >> 6714284

Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption.

J Hendel, A Nyfors.   

Abstract

The plasma concentration and urinary excretion of methotrexate were followed in twelve psoriatic patients after intravenous and oral doses of methotrexate ranging from 7.5 to 30 mg. In six of the patients, a nonlinear relation was found between the fractional amount of methotrexate excreted in the urine and the corresponding area under the plasma concentration-time curve. The methotrexate clearance was found to be increased during the initial high plasma concentration, probably due to saturation of the tubular reabsorption of methotrexate. Considerable interindividual variation was found in the apparent saturation point of the active reabsorption, but up to 500-800 ng/ml first order kinetics still applied. At plasma concentrations below saturation, the renal clearance of methotrexate ranged from 52-102 ml/min (mean +/- SD, 83 +/- 19.4 ml/min).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6714284     DOI: 10.1007/bf00546719

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.

Authors:  P R Leme; P J Creaven; L M Allen; M Berman
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

2.  THE RENAL EXCRETION OF FOLIC ACID.

Authors:  C A GORESKY; H WATANABE; D G JOHNS
Journal:  J Clin Invest       Date:  1963-12       Impact factor: 14.808

3.  A pharmacokinetic model for high-dose methotrexate infusions in man.

Authors:  S D Reich; N R Bachur; R H Goebel; M Berman
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 4.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

5.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

6.  Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern.

Authors:  J H Goldie; L A Price; K R Harrap
Journal:  Eur J Cancer       Date:  1972-08       Impact factor: 9.162

7.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

Review 8.  Methotrexate therapy of psoriasis. Effect and side effects with particular reference to hepatic changes. A survey.

Authors:  A Nyfors
Journal:  Dan Med Bull       Date:  1980-04

9.  Methotrexate megadose followed by folate rescue. II. Clearance patterns in patients receiving sequential megadose infusions.

Authors:  S Salasoo; M G Irving; A Freedman
Journal:  Med J Aust       Date:  1976-05-29       Impact factor: 7.738

10.  Dose dependent methotrexate elimination following bolus intravenous injection.

Authors:  J R Lawrence; W H Steele; J F Stuart; C A McNeill; J G McVie; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

View more
  15 in total

Review 1.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

3.  Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).

Authors:  P A Reece; I Stafford; J Russell; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine.

Authors:  Vaishnavi Ganti; Ellen A Walker; Swati Nagar
Journal:  Biomed Chromatogr       Date:  2013-03-12       Impact factor: 1.902

6.  Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis.

Authors:  Jaroslav Chládek; Jiøí Grim; Jiøina Martínková; Marie Simková; Jaroslava Vanìèková; Vìra Koudelková; Marie Noièková
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 7.  The practical use of methotrexate in psoriasis.

Authors:  J P Tung; H I Maibach
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 10.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.